United States of America
Andrew Powell, Esq., has served as a member of Aclaris Therapeutics’ board of directors since January 2017. Since May 2015, Mr. Powell served as Senior Vice President, General Counsel and Corporate Secretary of Medivation, Inc. through the company’s acquisition by Pfizer, Inc. until November 2016. Prior to Medivation, Inc., Mr. Powell served as Executive Vice President, General Counsel and Corporate Secretary of InterMune, Inc. from September 2013 to March 2015, where he helped the company prepare for the U.S. approval and launch of Esbriet® (pirfenidone) as a treatment for idiopathic pulmonary fibrosis and played a leadership role in InterMune’s acquisition by Swiss drug maker Roche Holdings AG. Early in his career, Mr. Powell held positions of increasing responsibility for nearly 15 years at the multi-national healthcare company Baxter International Inc., where he was instrumental in a series of transactions that established Baxter International throughout Asia. Subsequently, he was part of the senior team that repositioned CollaGenex Pharmaceuticals, Inc. as a leader in dermatology. Mr. Powell then served as Senior Vice President and General Counsel at ImClone Systems Inc., where he helped the company grow before playing a key role in a successful process that resulted in a sale to Eli Lilly and Company. Immediately prior to joining InterMune, he was Executive Vice President, General Counsel and Secretary at Cornerstone Therapeutics, Inc. through its successful sale to Chiesi Farmaceutici S.p.A. Mr. Powell holds a Bachelor of Arts from the University of North Carolina at Chapel Hill and a Juris Doctorate from Stanford Law School.
Host defense mechanisms,LPS effects on neurotransmitters